## M Odette Gore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2076044/publications.pdf Version: 2024-02-01



M ODETTE CODE

#	Article	IF	CITATIONS
1	A Pilot Study and Ecological Model of Smoking Cues to Inform Mobile Health Strategies for Quitting Among Low-Income Smokers. Health Promotion Practice, 2021, 22, 850-862.	1.6	3
2	Cardiovascular Risk Factor Knowledge among Monolingual Hispanics. Journal of Health Care for the Poor and Underserved, 2021, 32, 688-699.	0.8	0
3	A Point-of-Care Algorithm to Guide Proper Device Selection for Ambulatory Electrocardiography. Critical Pathways in Cardiology, 2021, 20, 140-142.	0.5	0
4	Combining Biomarkers and Imaging for Shortâ€Term Assessment of Cardiovascular Disease Risk in Apparently Healthy Adults. Journal of the American Heart Association, 2020, 9, e015410.	3.7	14
5	Clinical Relevance of the 99th Percentile Upper Reference Limit for High-Sensitivity Cardiac Troponin Assays. Clinical Chemistry, 2020, 66, 403-405.	3.2	9
6	Elements of Social Convoy Theory in Mobile Health for Palliative Care: Scoping Review. JMIR MHealth and UHealth, 2020, 8, e16060.	3.7	14
7	Racial Differences in Cardiovascular Biomarkers in the General Population. Journal of the American Heart Association, 2019, 8, e012729.	3.7	58
8	Identifying Familial Hypercholesterolemia Using a Blood Donor Screening Program With More Than 1 Million Volunteer Donors. JAMA Cardiology, 2019, 4, 685.	6.1	17
9	A Test in Context. Journal of the American College of Cardiology, 2016, 68, 2479-2486.	2.8	23
10	Effect of treatment with rosiglitazone on high-sensitivity cardiac troponin levels among patients with type 2 diabetes mellitus. Diabetes and Vascular Disease Research, 2016, 13, 113-118.	2.0	3
11	High prevalence of elevated haemoglobin A1C among adolescent blood donors: Results from a voluntary screening programme including 31,546 adolescents. Diabetes and Vascular Disease Research, 2015, 12, 272-278.	2.0	6
12	Homoarginine and Cardiovascular Outcome in the Population-Based Dallas Heart Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2501-2507.	2.4	73
13	ls cardiorespiratory fitness a determinant of cardiomyopathy in the setting of type 2 diabetes?. Diabetes and Vascular Disease Research, 2014, 11, 343-351.	2.0	5
14	Inaccuracy of Estimated Resting Oxygen Uptake in the Clinical Setting. Circulation, 2014, 129, 203-210.	1.6	69
15	Association of prediabetes by fasting glucose and/or haemoglobin A1c levels with subclinical atherosclerosis and impaired renal function: Observations from the Dallas Heart Study. Diabetes and Vascular Disease Research, 2014, 11, 11-18.	2.0	33
16	Age- and Sex-Dependent Upper Reference Limits for the High-Sensitivity Cardiac Troponin T Assay. Journal of the American College of Cardiology, 2014, 63, 1441-1448.	2.8	303
17	Insulin Resistance and Risk for Incident Heart Failure â^—. JACC: Heart Failure, 2013, 1, 537-539.	4.1	8
18	Discordant effects of rosiglitazone on novel inflammatory biomarkers. American Heart Journal, 2013, 165, 609-614.	2.7	10

M Odette Gore

#	Article	IF	CITATIONS
19	Symmetrical Dimethylarginine Predicts Mortality in the General Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2682-2688.	2.4	62
20	Drugs for type 2 diabetes mellitus: The imperative for cardiovascular outcome assessment. Diabetes and Vascular Disease Research, 2012, 9, 85-88.	2.0	4
21	Diabetes Mellitus and Trends in Hospital Survival After Myocardial Infarction, 1994 to 2006. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 791-797.	2.2	45
22	The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: A randomised, placebo-controlled trial. Diabetes and Vascular Disease Research, 2012, 9, 131-137.	2.0	16
23	Accuracy of Estimating Resting Oxygen Uptake and Implications for Hemodynamic Assessment. American Journal of Cardiology, 2012, 109, 594-598.	1.6	15
24	Adiponectin and cardiovascular risk profile in patients with type 2 diabetes mellitus: parameters associated with adiponectin complex distribution. Diabetes and Vascular Disease Research, 2011, 8, 190-194.	2.0	24
25	Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments. European Heart Journal, 2011, 32, 1832-1834.	2.2	24
26	Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment. Diabetes and Vascular Disease Research, 2011, 8, 101-108.	2.0	7
27	Diabetes and Heart Failure in Patients With Coronary Disease: Separating Markers From Mediators. Diabetes Care, 2010, 33, 2120-2122.	8.6	5
28	The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context. Diabetes and Vascular Disease Research, 2009, 6, 53-55.	2.0	33
29	Renal phosphate wasting due to tumor-induced osteomalacia: a frequently delayed diagnosis. Kidney International, 2009, 76, 342-347.	5.2	16
30	Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs. Current Cardiology Reports, 2009, 11, 258-263.	2.9	29